PMID- 29641976
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 77
DP  - 2018 Jul
TI  - MET amplification, expression, and exon 14 mutations in colorectal
      adenocarcinoma.
PG  - 108-115
LID - S0046-8177(18)30115-1 [pii]
LID - 10.1016/j.humpath.2018.03.024 [doi]
AB  - MET amplification, expression, and splice mutations at exon 14 result in
      dysregulation of the MET signaling pathway. The aim of this study was to identify
      the relationship between MET amplification, protein or mRNA expression, and
      mutations in colorectal cancer (CRC). MET immunohistochemistry was used for MET
      protein expression analysis, and fluorescence in situ hybridization was used for 
      MET amplification detection. Both analyses were performed in tissue microarrays
      containing 294 colorectal adenocarcinoma tissue samples and 131 samples of
      adjacent normal epithelial tissue. MET mRNA expression was examined by real-time 
      quantitative polymerase chain reaction in 72 fresh colorectal adenocarcinoma
      tissue samples and adjacent normal colon tissue. Polymerase chain reaction
      sequencing was performed to screen for MET exon 14 splice mutations in 59 fresh
      CRC tissue samples. Our results showed that MET protein expression was higher in 
      colorectal tumor tissue than in adjacent normal intestinal epithelium. Positive
      MET protein expression was associated with significantly poorer overall survival 
      and disease-free survival. Multivariate analysis revealed that positive MET
      protein expression was an independent risk factor for disease-free survival but
      not for overall survival. MET mRNA expression was upregulated in tumor tissues
      compared with the adjacent normal tissues. The incidence of MET amplification was
      4.4%. None of the patients was positive for MET mutation. Collectively, MET was
      overexpressed in colorectal adenocarcinoma, and its positive protein expression
      predicted a poorer outcome in CRC patients. Furthermore, according to our
      results, MET amplification and exon 14 mutation are extremely rare events in
      colorectal adenocarcinoma.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Department of Pathology, Shanghai Medical College, Fudan
      University, Shanghai, 200032, China; Institute of Pathology, Fudan University,
      Shanghai, 200032, China. Electronic address: doc_zm@163.com.
FAU - Li, Guichao
AU  - Li G
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China; Department of Radiation Oncology, Fudan University Shanghai Cancer
      Center, Shanghai, 200032, China. Electronic address: guichaoli11@163.com.
FAU - Sun, Xiangjie
AU  - Sun X
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China. Electronic address: emmasun93@163.com.
FAU - Ni, Shujuan
AU  - Ni S
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China. Electronic address: nsj616@126.com.
FAU - Tan, Cong
AU  - Tan C
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China. Electronic address: saratancong@163.com.
FAU - Xu, Midie
AU  - Xu M
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China. Electronic address: xumd27202003@sina.com.
FAU - Huang, Dan
AU  - Huang D
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China. Electronic address: dianehuangfdcc@gmail.com.
FAU - Ren, Fei
AU  - Ren F
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China. Electronic address: renfei0319@163.com.
FAU - Li, Dawei
AU  - Li D
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China; Department of Colorectal Surgery, Fudan University Shanghai Cancer
      Center, Shanghai, 200032, China. Electronic address: davidleehero@126.com.
FAU - Wei, Ping
AU  - Wei P
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Institute of Pathology, Fudan University, Shanghai, 200032, China;
      Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
      200032, China; Institutes of Biomedical Sciences, Fudan University, Shanghai,
      200032, China; Cancer Institute, Fudan University Shanghai Cancer Center,
      Shanghai, 200032, China. Electronic address: weiping@fudan.edu.cn.
FAU - Du, Xiang
AU  - Du X
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai,
      200032, China; Department of Pathology, Shanghai Medical College, Fudan
      University, Shanghai, 200032, China; Institute of Pathology, Fudan University,
      Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan 
      University, Shanghai, 200032, China; Institutes of Biomedical Sciences, Fudan
      University, Shanghai, 200032, China. Electronic address: dx2008cn@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180408
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Adenocarcinoma/diagnosis/genetics/metabolism/*pathology
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Colorectal Neoplasms/diagnosis/*metabolism/*pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Amplification/physiology
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Lung Neoplasms/genetics/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Proto-Oncogene Proteins c-met/*genetics/metabolism
OTO - NOTNLM
OT  - *Amplification
OT  - *Biomarker
OT  - *Colorectal cancer
OT  - *MET
OT  - *exon 14 mutation
EDAT- 2018/04/12 06:00
MHDA- 2019/04/10 06:00
CRDT- 2018/04/12 06:00
PHST- 2017/12/21 00:00 [received]
PHST- 2018/03/28 00:00 [revised]
PHST- 2018/03/30 00:00 [accepted]
PHST- 2018/04/12 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2018/04/12 06:00 [entrez]
AID - S0046-8177(18)30115-1 [pii]
AID - 10.1016/j.humpath.2018.03.024 [doi]
PST - ppublish
SO  - Hum Pathol. 2018 Jul;77:108-115. doi: 10.1016/j.humpath.2018.03.024. Epub 2018
      Apr 8.